Interferon and Cancer

  • Karol Sikora

Table of contents

  1. Front Matter
    Pages i-viii
  2. Karol Sikora
    Pages 1-9
  3. David Tyrrell
    Pages 11-15
  4. Armin H. Ramel, W. Courtney McGregor, Zofia E. Dziewanowska
    Pages 17-32
  5. Bryan R. G. Williams
    Pages 33-52
  6. Annapurna Vyakarnam
    Pages 53-63
  7. Sandra Horning
    Pages 77-83
  8. Ama Rohatiner
    Pages 85-94
  9. Terence J. Priestman
    Pages 95-101
  10. Ernest C. Borden, Jordan U. Gutterman, James F. Holland, Thomas L. Dao
    Pages 103-112
  11. Karin Mattson, Lars R. Holsti
    Pages 113-119
  12. John R. Neefe
    Pages 121-127
  13. Satoshi Ueda, Kimiyoshi Hirakawa, Yoshio Nakagawa, Kenzo Suzuki, Tsunataro Kishida
    Pages 129-139
  14. Lars-Åke Broström, Ulf Nilsonne
    Pages 141-152
  15. Geoffrey M. Scott
    Pages 153-168
  16. Drago Ikić
    Pages 169-181
  17. Arthur S. Levine, Stephen A. Sherwin
    Pages 183-201
  18. Howard M. Smedley, Terence Wheeler
    Pages 203-210
  19. Back Matter
    Pages 211-215

About this book

Introduction

Interferon was first discovered in 1957. Over the last five years it has become almost a household word. Many believe it to be a drug with already proven efficacy against cancer and viral infection. The media has distorted any cool scientific view of the data available. We have learned much about the complexity of the interferon system. We know some of the switches involved in interferon gene expression and its secretion by virally and immune stimulated cells. We also know that it binds to a cell surface receptor, mediating its complex effects on target cells by a series of second messengers. The advent of the new techniques of modern molecular biology, such as monoclonal antibodies and gene cloning, has had tremendous impact on the rate of acquisition of knowledge. Such techniques have provided us with almost unlimited quantities of highly purified interferon for clinical trial in patients with a spectrum of infectious and malignant diseases. The information we have gathered raises many more questions. Why should there be several families of interferon genes? What is their true physiolo­ gical role? How are they interrelated functionally? Interferon is clearly a cellular hormone providing a means of communication between cells. ~fhether it has clinical value in the management of patients with diseased cells remains to be seen. This book sum­ marises our current knowledge of interferons as possible an- cancer agents. It is clear interferon is no penicillin for cancer.

Keywords

brain tumors cell clinical trial hormones interferon leukemia lymphoma molecular biology

Editors and affiliations

  • Karol Sikora
    • 1
  1. 1.Ludwig Institute for Cancer ResearchCambridgeUK

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4684-1170-6
  • Copyright Information Springer-Verlag US 1983
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4684-1172-0
  • Online ISBN 978-1-4684-1170-6
  • About this book